机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China首都医科大学宣武医院[2]National Clinical Research Center for Geriatric Diseases, Beijing, China[3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China[4]Beijing Institute for Brain Disorders, Beijing, China[5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
National Natural Science
Foundation of China (81473373, 81874351, 81673406);
National Science and Technology Major Project of China (No.
2015ZX09101-016); Capital Science and Technology Leading
Talent Training Project (Z191100006119017), and Beijing
Hospitals Authority Ascent Plan (DFL20190803).
第一作者机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China[2]National Clinical Research Center for Geriatric Diseases, Beijing, China[3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China[4]Beijing Institute for Brain Disorders, Beijing, China[5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
通讯作者:
通讯机构:[1]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China[2]National Clinical Research Center for Geriatric Diseases, Beijing, China[3]Beijing Engineering Research Center for Nervous System Drugs, Beijing, China[4]Beijing Institute for Brain Disorders, Beijing, China[5]Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
推荐引用方式(GB/T 7714):
Wei Weipeng,Ma Denglei,Li Lin,et al.Progress in the Application of Drugs for the Treatment of Multiple Sclerosis.[J].FRONTIERS IN PHARMACOLOGY.2021,12:doi:10.3389/fphar.2021.724718.
APA:
Wei Weipeng,Ma Denglei,Li Lin&Zhang Lan.(2021).Progress in the Application of Drugs for the Treatment of Multiple Sclerosis..FRONTIERS IN PHARMACOLOGY,12,
MLA:
Wei Weipeng,et al."Progress in the Application of Drugs for the Treatment of Multiple Sclerosis.".FRONTIERS IN PHARMACOLOGY 12.(2021)